Edition:
India

Prothena Reports Results From The Phase 3 Vital Amyloidosis Study Of Neod001 In Al Amyloidosis


Friday, 19 Apr 2019 

April 18 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS RESULTS FROM THE PHASE 3 VITAL AMYLOIDOSIS STUDY OF NEOD001 (BIRTAMIMAB) IN AL AMYLOIDOSIS.PROTHENA - RESULTS FROM FINAL ANALYSIS OF COMPOSITE PRIMARY ENDPOINT WERE CONSISTENT WITH FUTILITY ANALYSIS REPORTED IN APRIL 2018 FROM PHASE 3 VITAL STUDY.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - NONE OF SECONDARY ENDPOINTS ACHIEVED STATISTICAL SIGNIFICANCE IN TOTAL STUDY POPULATION OF PHASE 3 VITAL STUDY.PROTHENA CORPORATION PLC - NEOD001 AND CONTROL ARMS HAD SIMILAR FREQUENCIES OF TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS. 

Company Quote

8.94
-0.29 -3.14%
1:30am IST